Результаты поиска

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

The management of chronic myeloid leukemia with BCR-ABL1 tyrosine kinase inhibitors has evolved chronic myeloid leukemia into a chronic, manageable disease. A patient-centered approach is important for the appropriate management of chronic myeloid leukemia and optimization of long-term treatment outcomes. The pharmacist plays a key role in treatment selection, monitoring drug-drug interactions, identification and management of adverse events, and educating patients on adherence. The combination of tyrosine kinase inhibitors with unique safety profiles and individual patients with unique medica

Совпадение в полном тексте источника
… John’s Wort). 1 – 5 Additionally, concomitant use of CYP3A inhibitors (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir) should also be avoided in CML patients taking TKIs, since it could increase …

Abstracts for NAPCON 2025

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Мукоадгезивные наноэмульсии для доставки нозы в мозг диметилфумарат: разработка, характеристика и доказательство согласия

Фон. Диметилфумарат (ДМП) является утвержденным терапевтическим агентом для лечения множественного склероза, известным своими противовоспалительными и нейрозащитными свойствами. Однако его пероральное управление часто сопровождается побочными эффектами желудочно-кишечного кишечника, что ограничивает его терапевтический потенциал. В настоящем исследовании была разработана новая формула наноэмульсии (NE), которая была охарактеризована с целью усиления воздействия ДМП в цереброспинарной жидкости (CSF) после внутринационального администрирования. Методы: Состав был подготовлен методом самоэмульсиф

Руководящие принципы и рекомендации для anti-CD38-based Терапия в области клинической практики для повторной/отправленной миеломы: от Пантихоокеанской рабочей группы по миеломе.

Anti-CD38 Моноклональные антитела (mAbs), включая Daratumumumab и Isatuximab, стали ключевыми компонентами лечения повторной/редактированной множественной миеломы (RRMMM). Этот экспертный консенсус обеспечивает основанные на фактических данных руководящие указания в отношении их оптимального использования, включая выбор режима, особые соображения в отношении пожилых или слабых пациентов и лечение подгрупп высокого риска. Ключевые темы, которые были рассмотрены, включают в себя выбор anti-CD38-based - режимы, стратификация пациентов в результате слабости и коморбидности, стратегии регулирования

Совпадение в полном тексте источника
… receive influenza and recombinant zoster vaccines before therapy initiation Fungal | Candida species, Aspergillus species, Cryptococcus neoformans | Fungal biomarkers (galactomannan, beta-D-glucan) Periodic chest imaging Fungal culture if infection suspected | Fluconazole for candidiasis Posaconazole or voriconazole …

Safety of solid oncology drugs in older patients: a narrative review.

The older population represents ∼50%-60% of the population of newly diagnosed patients with cancer. Due to physiological and pathological aging and the increased presence of comorbidities and frailty factors, this population is at higher risk of serious toxicity from anticancer drugs and, consequently, often under-treated. Despite the complexity of these treatments, a good knowledge of the pharmacology of anticancer drugs and potentially risky situations can limit the emergence of potentially lethal toxicities in this population. This review focuses on optimizing systemic oncology treatments f

Совпадение в полном тексте источника
… The most frequently prescribed CYP3A4 inhibitors are azole antifungal agents (voriconazole, pasaconazole, fluconazole), antivirals (ritonavir, saquinavir), and herbal remedies (grapefruit, Seville orange, goldenseal) 33 among others. …

Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.

Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the presence of comorbidities, polypharmacy, frailty and adverse events of disease-targeted drugs. The rapid changes in MM treatment resulting from constant innovations in this area, together with the introduction of numerous new drugs with distinct mechanisms of action and toxicity profiles, have led to an increased complexity in the therapeutic decision-making and patient management processes. The prolonged exposure to nove

Совпадение в полном тексте источника
… patients on high-dose dexamethasone (doses ≥40mg x 4 days per week) or with RRMM; dapsone or atovaquone as an alternative to cotrimoxazole (prophylaxis of Pneumocystis jirovecii infection) | Fluconazole or micafungin in case of severe mucositis and/or prolonged neutropenia (ANC ≤100 cells/µL for≥7 days) Voriconazole …

Регулирование заразительных осложнений в создании химической антигенной приемной клетки (CAR-T)

Химерическая антигенная рецепторная T-клетка (CAR T-клетка) изменила парадигму управления лимфомой не Ходжкина (NHL) и множественной миеломой. Осложнения, связанные с инфекцией, стали предметом озабоченности, которая может возникнуть в процессе лечения и привести к заболеваемости и смертности. В ходе этого обзора мы классифицировали осложнения, связанные с инфекцией, в three Категория, этап предварительного вливания с момента предварительного лимфодерации (LD) до дня zero, ранний этап от дня вливания до дня 30 после введения в эксплуатацию и с запозданием изо дня в день 30 и дальше. Инфекции,

Совпадение в полном тексте источника
… Continue until CD4 counts > 200 or at least 6 months Antifungals | Fluconazole 200mg PO daily (standard risk) Posaconazole 300mg PO daily | Micafungin 50 IV q24H ( if LFT abnormality) | Onset of neutropenia ( ANC < 500/mm 3 ) | Recovery of neutropenia ( ANC > 500/mm 3 ) Antifungals in high risk * | Voriconazole …

Клеточная терапия ревматических и мышечных заболеваний.

Значительная часть пациентов, у которых диагностированы ревматологические и мускулоскелетные заболевания (РМ), демонстрируют устойчивость к традиционной терапии или испытывают повторяющиеся симптомы. Эти заболевания, к которым относятся аутоиммунные расстройства, такие, как множественный склероз, ревматоидный артрит и системный волшебный эритематос, характеризуются наличием автоматически реактивных клеток B, играющих решающую роль в их патогенезе. Стойкость этих самореактивных клеток В в лимфатических органах и воспаленных тканях снижает эффективность таких моноклонных антител, как ритуксимаб,

Совпадение в полном тексте источника
… For patients at risk of fungal infections, especially those with prolonged neutropenia or receiving high-dose corticosteroids, antifungal prophylaxis with fluconazole or voriconazole is advised [ 197 ]. …

Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices.

Cytotoxic drugs are highly efficacious and also have low therapeutic index. A great degree of caution needs to be exercised in their usage. To optimize the efficacy these drugs need to be given at maximum tolerated dose which leads to significant amount of toxicity to the patient. The fine balance between efficacy and safety is the key to the success of cytotoxic chemotherapeutics. However, it is possibly more rewarding to obtain that balance for this class drugs as the frequency of drug related toxicities are higher compared to the other therapeutic class and are potentially life threatening

Совпадение в полном тексте источника
… Drug class and agents | Interaction with oral busulfan | Interaction with i.v. busulfan Antifungals: Itraconazole Fluconazole Voriconazole Posaconazole Isavuconazole | Likely Exercise caution | Likely Exercise caution and avoid starting these drugs during preconditioning Antiepileptic: Phenytoin | Potential …

ECC-4 Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Septic shock in the immunocompromised cancer patient: a narrative review.

Immunosuppressed patients, particularly those with cancer, represent a momentous and increasing portion of the population, especially as cancer incidence rises with population growth and aging. These patients are at a heightened risk of developing severe infections, including sepsis and septic shock, due to multiple immunologic defects such as neutropenia, lymphopenia, and T and B-cell impairment. The diverse and complex nature of these immunologic profiles, compounded by the concomitant use of immunosuppressive therapies (e.g., corticosteroids, cytotoxic drugs, and immunotherapy), superimpose

Совпадение в полном тексте источника
… These range from the use of antibiotics (e.g., levofloxacin, trimethoprim/sulfamethoxazole, and cefpodoxime) to prevent bacterial infections in patients receiving treatments that cause neutropenia for over a week to the use of antifungals (e.g., fluconazole, posaconazole, voriconazole) in patients after …

TB AND OTHER CHEST INFECTIONS

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

:: 45th Ежегодное совещание Европейского общества по трансплантации крови и костного мозга: Врачи - сессия плаката.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Rare Diseases of the Orbit.

This article provides an overview of rare orbital diseases. Congenital malformations, inflammatory diseases, benign and malignant neoplasias are described. Although it represents a relatively small area of the body the orbit contains multiple different tissues. Therefore, a great variety of diseases can be found within the orbital space. That is the reason, why both the completeness and the level of detail in the description of particular diseases must be somewhat limited. Nevertheless, clinical manifestations, important aspects of diagnosis, treatment strategies, and, when specific data are a

Совпадение в полном тексте источника
… After oral therapy with voriconazole for 6 weeks and sufficient pain therapy with gabapentin and amitriptyline, there was subjectively complete regression of the pain; on the MRI performed 6 months later, only limited regression was found (see Fig. 8d ). … procedures 59 Important differential diagnoses bacterial cellulitis, cavernous sinus thrombosis, Tolosa-Hunt syndrome tumors of the orbital apex or the sphenoid sinus Therapy antifungal therapy with liposomal amphotericin B until exclusion of mucormycosis, followed by a shift to the more effective voriconazole …

BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.

The BCL-2 family of proteins plays a central role in the regulation of apoptosis, with BCL-2 and BCL-xL representing two of its most prominent antiapoptotic members. This review explores the molecular regulation of BCL-2 and BCL-xL genes, emphasizing the structural domains that define the functions of the broader BCL-2 family. Beyond their canonical roles in preventing mitochondrial outer membrane permeabilization, both proteins contribute significantly to cancer development. Their overexpression enhances invasiveness and tumor progression, supports angiogenesis, and critically modulates cellu

Совпадение в полном тексте источника
… Trials in advanced hematologic or solid tumors ( NCT04214093 ) were initiated, as well as studies evaluating AZD0466 combined with Voriconazole ( NCT04865419 ) and with other anticancer agents in non-Hodgkin lymphoma ( NCT05205161 ). …

Overview of infectious complications among CAR T- cell therapy recipients.

Chimeric antigen receptor-modified T cell (CAR T-cell) therapy has revolutionized the management of hematological malignancies. In addition to impressive malignancy-related outcomes, CAR T-cell therapy has significant toxicity-related adverse events, including cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), immune effector cell-associated hematotoxicity (ICAHT), and opportunistic infections. Different CAR T-cell targets have different epidemiology and risk factors for infection, and these targets result in different long-term immunodeficiency st

Совпадение в полном тексте источника
… | Alternative agent (s) | Comment Antibacterial | Levofloxacin | | Start when ANC < 500 and continue until neutrophil recovery (ANC >500 for at least 3 days) Antifungal | Fluconazole | Micafungin | Start when ANC<500 and continue until neutrophil recovery (ANC >500 for at least 3 days) Anti-mold | Voriconazole …

Е-постеры.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.

The introduction of chimeric antigen receptor T (CAR-T) cell and bispecific antibody (BsAb) therapies has revolutionized multiple myeloma (MM) treatment, offering exceptional efficacy, and culminating in recent regulatory approval. However, these therapies have brought unique toxicity challenges, manifesting not only with the well-established cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), but also with the emergence of other common and equally distinctive toxicities, including cytopenias, hypogammaglobulinemia, infections, and the rare but l

Совпадение в полном тексте источника
… Antifungal prophylaxis should include fluconazole or echinocandins, considering posaconazole or voriconazole in patients at higher risk for mould infections [ 7 , 80 , 120 ]. …

Acute and Chronic Respiratory Failure in Cancer Patients

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Voriconazole is the drug of choice; however, combination therapy may be required. …

POSTER PRESENTATIONS

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.